simCYD15_twostage: Simulated CYD15 Two-Phase Data Set

In brendalewisprice/IPCWTMLE2Phase: Inverse Probability of Censoring Weighted Targeted Minimum Loss-based Estimation for Two-Phase STudies

Description

Data simulated to mimic the CYD15 Tetravalent Dengue Vaccine Trial conducted by Sanofi-Pasteur

Usage

data(simCYD15_twostage)

Format

A data frame simulated to mimic a phase 3 dengue vaccine efficacy trial with 20500 rows and the following 40 variables:

X

Row number

STUDYID

Study name

SUBJID

Subject ID

VACC

Vaccination status: vaccine=1; placebo=0

AGEYRS

Subject age at enrollment

SEX

M=male; F=female

Male

Binary indicator: 1=male, 0=female

COUNTRY

Country code

IDN-MEX

Country code indicator variables

VCD

Any VCD (virally confirmed dengue)=1, no VCD=0

VCD_Sero1-VCD_Sero4

Indicator of VCD specific serotype 1 - serotype 4

baseline_PRNT_Sero1-baseline_PRNT_Sero4

Baseline serotype PRNT titers for serotypes 1-4

baseline_PRNT_SeroAverage

Geometric mean of baseline PRNT titers

M13_PRNT_Sero1-M13_PRNT_Sero4

M13 serotype PRNT titers for serotypes 1-4

M13_PRNT_SeroAverage

Geometric mean of M13 PRNT titers

M13_MNv2_Sero1-M13_MNv2_Sero4

M13 serotype MNv2 titers for serotypes 1-4

M13_MNv2_SeroAverage

Geometric mean of M13 MNv2 titers

weight

Observation level sampling weight for sampling to phase-two

delta

Indicator of sampling to phase-two sample

#'

References

Villar et al. (2015) New England Journal of Medicine 372:112-123

brendalewisprice/IPCWTMLE2Phase documentation built on Nov. 4, 2019, 8:12 a.m.